Core Viewpoint - Psyence Biomedical Ltd. (NASDAQ:PBM) is currently in the spotlight due to its planned reverse stock split, which aims to increase the stock price and attract investors [1] Group 1: Reverse Stock Split - PBM initially announced a reverse stock split at a ratio of 1-for-6.25, set to take effect on January 20, 2026, but has postponed this action [2][6] - The company plans to announce a new date for the reverse stock split in the future, and until then, the stock will continue trading under the symbol "PBM" without adjustments [2] Group 2: Stock Performance - Currently, PBM's stock is priced at $0.67, with a market capitalization of approximately $478,000 [3] - The stock has experienced significant volatility, with a 52-week high of $108.59 and a low of $0.615 [3][6] - The company's price-to-earnings (P/E) ratio is 0.17, indicating that the stock is trading at a low price relative to its earnings [3] Group 3: Analyst Ratings - Analysts maintain a cautious outlook on PBM, with Weiss Ratings reaffirming a "sell (e+)" rating and the consensus rating also being "Sell" [4][6] Group 4: Trading Activity - PBM's trading volume on the Nasdaq exchange is 506,821 shares, indicating active trading [5] - The stock's 50-day moving average is $1.48, while the 200-day moving average is $3.18, reflecting a downward trend over the past year [5] - The company's beta of 0.32 suggests that the stock is less volatile compared to the overall market [5]